- Home
- INDV vs VRDN Comparison
INDV vs VRDN Comparison
Compare INDV & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDV
- VRDN
- Stock Information
- Founded
- INDV 1994
- VRDN 2006
- Country
- INDV United States
- VRDN United States
- Employees
- INDV N/A
- VRDN N/A
- Industry
- INDV Biotechnology: Pharmaceutical Preparations
- VRDN Medical Specialities
- Sector
- INDV Health Care
- VRDN Health Care
- Exchange
- INDV Nasdaq
- VRDN Nasdaq
- Market Cap
- INDV 1.3B
- VRDN 1.6B
- IPO Year
- INDV N/A
- VRDN N/A
- Fundamental
- Price
- INDV $12.01
- VRDN $19.72
- Analyst Decision
- INDV Strong Buy
- VRDN Strong Buy
- Analyst Count
- INDV 2
- VRDN 11
- Target Price
- INDV $16.00
- VRDN $37.63
- AVG Volume (30 Days)
- INDV 1.1M
- VRDN 1.4M
- Earning Date
- INDV 10-24-2024
- VRDN 11-12-2024
- Dividend Yield
- INDV N/A
- VRDN N/A
- EPS Growth
- INDV N/A
- VRDN N/A
- EPS
- INDV N/A
- VRDN N/A
- Revenue
- INDV $1,182,000,000.00
- VRDN $302,000.00
- Revenue This Year
- INDV $7.32
- VRDN $2.55
- Revenue Next Year
- INDV N/A
- VRDN N/A
- P/E Ratio
- INDV N/A
- VRDN N/A
- Revenue Growth
- INDV 13.44
- VRDN N/A
- 52 Week Low
- INDV $7.33
- VRDN $11.40
- 52 Week High
- INDV $23.22
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- INDV 68.07
- VRDN 49.14
- Support Level
- INDV $11.47
- VRDN $20.06
- Resistance Level
- INDV $12.20
- VRDN $23.65
- Average True Range (ATR)
- INDV 0.30
- VRDN 1.05
- MACD
- INDV 0.01
- VRDN 0.16
- Stochastic Oscillator
- INDV 84.52
- VRDN 49.45
About INDV Indivior PLC
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.